Skip to main content

Advertisement

SpringerLink
Log in

Rituximab Off Label Use for Difficult-To-Treat Auto-Immune Diseases: Reappraisal of Benefits and Risks

  • Published:
Clinical Reviews in Allergy & Immunology Aims and scope Submit manuscript

Abstract

Rituximab is increasingly used off label for difficult-to-treat auto-immune diseases. We reviewed the main case series or clinical studies to identify the best indications of rituximab and the situations at substantial risks for adverse events. Refractory immune thrombocytopenic purpura was the main indication. However, the long term benefit-to-risk ratio of rituximab treatment before or after splenectomy is unknown. A single 375 mg/m2 infusion may be as efficacious as the classical four infusions cycle. Rituximab is the best treatment for cold agglutinin disease. In warm agglutinin auto-immune anaemia, its efficacy has essentially been reported in chronic lymphocytic leukemia (CLL) patients and in children. In CLL patients, lethal adverse events occurred in patients also receiving cyclophosphamide. Rituximab seems to have an interesting benefit-to-risk ratio in Wegener granulomatosis (excepted in granulomatous lesions), HCV-associated symptomatic cryoglobulinemia in patients unresponsive to anti-viral therapy, pemphigus and thrombotic thrombocytopenic purpura. Efficacy and safety data in lupus are difficult to interpret. Serum sickness disease is not exceptional in immune thrombocytopenic purpura (ITP), lupus and sicca syndrome patients. A substantial infectious risk has been reported in pemphigus patients and in post-renal transplant cryoglobulinemia. Double-blind randomised controlled trials and phase IV studies are mandatory in most clinical settings to confirm the overall favourable perception of rituximab benefit to risk ratio.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Franchini M et al (2006) The efficacy of rituximab in the treatment of inhibitor-associated hemostatic disorders. Thromb Haemost 96:119–125

    PubMed  CAS  Google Scholar 

  2. Kimby E (2005) Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 31:456–473

    Article  PubMed  CAS  Google Scholar 

  3. Vianelli N et al (2005) Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases. Haematologica 90:72–77

    PubMed  Google Scholar 

  4. Bennett CM et al (2006) Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 107:2639–2642

    Article  PubMed  CAS  Google Scholar 

  5. Saleh MN et al (2000) A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin Oncol 27:99–103

    PubMed  CAS  Google Scholar 

  6. Godeau B et al (2006) Rituximab is an alternative to splenectomy in adults with chronic immune thrombocytopenic purpura: results of a multicenter prospective phase 2 study. Blood 108,145a, abstract 478.

  7. Kojouri K et al (2004) Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 104:2623–2634

    Article  PubMed  CAS  Google Scholar 

  8. Taube T et al (2005) Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in childhood. Haematologica 90:281–283

    PubMed  CAS  Google Scholar 

  9. D’Arena G et al (2006) Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Am J Hematol 81:598–602

    Article  PubMed  CAS  Google Scholar 

  10. Zaja F et al (2003) Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases. Leuk Lymphoma 44:1951–1955

    Article  PubMed  CAS  Google Scholar 

  11. Narat S et al (2005) Rituximab in the treatment of refractory autoimmune cytopenias in adults. Haematologica 90:1273–1274

    PubMed  CAS  Google Scholar 

  12. Trape G et al (2003) Rituximab chimeric anti-CD20 monoclonal antibody treatment for refractory hemolytic anemia in patients with lymphoproliferative disorders. Haematologica 88:223–225

    PubMed  CAS  Google Scholar 

  13. Shanafelt TD et al (2003) Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. Mayo Clin Proc 78:1340–1346

    Article  PubMed  CAS  Google Scholar 

  14. Zecca M et al (2003) Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 101:3857–3861

    Article  PubMed  CAS  Google Scholar 

  15. Berentsen S et al (2006) Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica 91:460–466

    PubMed  Google Scholar 

  16. Schollkopf C et al (2006) Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. Leuk Lymphoma 47:253–260

    Article  PubMed  CAS  Google Scholar 

  17. Berentsen S et al (2004) Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood 103:2925–2928

    Article  PubMed  CAS  Google Scholar 

  18. Tokunaga M et al (2007) Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 66:470–475

    Article  CAS  Google Scholar 

  19. Vallerskog T et al (2006) Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 8:R167

    Article  PubMed  CAS  Google Scholar 

  20. Leandro MJ et al (2005) B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 44:1542–1545

    Article  CAS  Google Scholar 

  21. Smith KG et al (2006) Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 54:2970–2982

    Article  PubMed  CAS  Google Scholar 

  22. Willems M et al (2006) Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr 148:623–627

    Article  PubMed  CAS  Google Scholar 

  23. Vigna-Perez M et al (2006) Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 8:R83

    Article  PubMed  CAS  Google Scholar 

  24. Sfikakis PP et al (2005) Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 52:501–513

    Article  PubMed  CAS  Google Scholar 

  25. Marks SD et al (2005) B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 52:3168–3174

    Article  PubMed  CAS  Google Scholar 

  26. Looney RJ et al (2004) B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 50:2580–2589

    Article  PubMed  CAS  Google Scholar 

  27. Gottenberg JE et al (2005) Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 64:913–920

    Article  PubMed  CAS  Google Scholar 

  28. Ginzler EM et al (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353:2219–2228

    Article  PubMed  CAS  Google Scholar 

  29. Seror R et al (2007) Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. Ann Rheum Dis 66:351–357

    Article  PubMed  CAS  Google Scholar 

  30. Pijpe J et al (2005) Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum 52:2740–2750

    Article  PubMed  CAS  Google Scholar 

  31. Levine TD (2005) Rituximab in the treatment of dermatomyositis: an open-label pilot study Arthritis Rheum 52:601–607

    Article  PubMed  CAS  Google Scholar 

  32. Noss EH et al (2006) Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol 33:1021–1026

    PubMed  Google Scholar 

  33. Stasi R et al (2006) Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford) 45:1432–1436

    Article  CAS  Google Scholar 

  34. Aries PM et al (2006) Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 65:853–858

    Article  PubMed  CAS  Google Scholar 

  35. Keogh KA et al (2006) Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 173:180–187

    Article  PubMed  CAS  Google Scholar 

  36. Eriksson P (2005) Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 257:540–548

    Article  PubMed  CAS  Google Scholar 

  37. Sansonno D et al (2003) Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 101:3818–3826

    Article  PubMed  CAS  Google Scholar 

  38. Roccatello D et al (2004) Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 19:3054–3061

    Article  PubMed  CAS  Google Scholar 

  39. Zaja F et al (2003) Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 101:3827–3834

    Article  PubMed  CAS  Google Scholar 

  40. Bryce AH et al (2006) Response to rituximab in patients with type II cryoglobulinemia. Clin Lymphoma Myeloma 7:140–144

    Article  PubMed  CAS  Google Scholar 

  41. Basse G et al (2006) Rituximab therapy for mixed cryoglobulinemia in seven renal transplant patients. Transplant Proc 38:2308–2310

    Article  PubMed  CAS  Google Scholar 

  42. Lake-Bakaar G et al (2007) Hepatitis C virus and alanine aminotransferase kinetics following B-lymphocyte depletion with rituximab: evidence for a significant role of humoral immunity in the control of viremia in chronic HCV liver disease. Blood 109:845–846

    Article  PubMed  CAS  Google Scholar 

  43. Schmidt E et al (2006) Rituximab in refractory autoimmune bullous diseases. Clin Exp Dermatol 31:503–508

    Article  PubMed  CAS  Google Scholar 

  44. Schmidt E et al (2007) Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol 156:352–356

    Article  PubMed  CAS  Google Scholar 

  45. Ahmed AR et al (2006) Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 355:1772–1779

    Article  PubMed  CAS  Google Scholar 

  46. Bohm M et al (2005) The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine. Br J Haematol 129:644–652

    Article  PubMed  CAS  Google Scholar 

  47. Scully M et al (2007) Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol 136:451–461

    Article  PubMed  CAS  Google Scholar 

  48. Fakhouri F et al (2005) Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood 106:1932–1937

    Article  PubMed  CAS  Google Scholar 

  49. Heidel F et al (2007) Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia. Thromb Haemost 97:228–233

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service de Pharmacologie Clinique, Unité de Pharmacoépidémiologie, CHU de Toulouse, IFR INSERM 126, EA3696, Toulouse, France

    Laurent Sailler

  2. Service de Médecine Interne, Salle Le Tallec, Pavillon Dieulafoy, Hôpital Purpan, CHU de Toulouse, 31059, Toulouse, Cédex, France

    Laurent Sailler

Authors
  1. Laurent Sailler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Laurent Sailler.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sailler, L. Rituximab Off Label Use for Difficult-To-Treat Auto-Immune Diseases: Reappraisal of Benefits and Risks. Clinic Rev Allerg Immunol 34, 103–110 (2008). https://doi.org/10.1007/s12016-007-8020-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12016-007-8020-7

Keywords

Search

Navigation